Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs

CMAJ. Canadian Medical Association Journal

Volumn 180, Issue 13, 2009, Pages 1310-1316

  Pérez, Norma ^a   Moisan, Jocelyne ^a,b   Sirois, Caroline ^a,b   Poirier, Paul ^b,c   Grégoire, Jean Pierre ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CHLORPROPAMIDE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INSULIN; METFORMIN; NEUROLEPTIC AGENT; REPAGLINIDE; THIAZIDE DIURETIC AGENT; TOLBUTAMIDE;

AGED; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; GERIATRIC PATIENT; HOSPITAL ADMISSION; HUMAN; INSULIN TREATMENT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POPULATION RESEARCH; PROPORTIONAL HAZARDS MODEL; CANADA; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PROPORTIONAL HAZARDS MODELS; QUEBEC; TREATMENT OUTCOME;

EID: 67650708113     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.080547     Document Type: Article

References (33)

1. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12.
2. Canadian Diabetes Association. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003;27(Suppl 2):S1-152.
3. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72.
4. American Diabetes Association. Standards of medical care in diabetes 2008. Diabetes Care 2008;31(Suppl 1):S12-54.
5. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297-303.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
7. Donnan PT, Steinke DT, Newton RW, et al. Changes in treatment after the start of oral hypoglycaemic therapy in type 2 diabetes: a population-based study. Diabet Med 2002;19:606-10.
8. Polonsky KS, Sturis J, Bell GI. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334:777-83.
9. Groop LC, Pelkonen R, Koskimies S, et al. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 1986;9: 129-33.
10. Groop L, Schalin C, Franssila-Kallunki A, et al. Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med 1989;87:183-90.
11. Johnson SB. Methodological issues in diabetes research. Measuring adherence. Diabetes Care 1992;15:1658-67.
12. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
13. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical (ATC) classification index. Oslo (Norway): the centre; 2000.
14. Schneeweiss S, Seeger J, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64.
15. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:4059-67.
16. Pandit MK, Burke J, Gustafson AB, et al. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993;118:529-39.
17. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-32.
18. Phillips A. Experiences of patients with type 2 diabetes starting insulin therapy. Nurs Stand 2007;21:35-41.
19. Thompson WG. An assault on old friends: thiazide diuretics under siege. Am J Med Sci 1990;300:152-8.
20. Barzilay JI, Davis BR, Cutler JA, et al.; ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006;166:2191-201.
21. O'Byrne S, Feely J. Effects of drugs on glucose tolerance in non-insulin-dependent diabetics (Part I). Drugs 1990;40:6-18.
22. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23:463-73.
23. Gress TW, Nieto FJ, Shahar E, et al.; The Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-12.
24. Spoelstra JA, Stolk RP, Heerdink ER, et al. Refill compliance in type 2 diabetes mellitus: A predictor of switching to insulin therapy? Pharmacoepidemiol Drug Saf 2003;12:121-7.
25. Spoelstra JA, Stol RP, de Bruyne MC, et al. Factors associated with switching from oral hypoglycaemic agents to insulin therapy. Neth J Med 2002;60:243-8.
26. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218.
27. Berger W. Insulin therapy in the elderly type 2 diabetic patient. Diabetes Res Clin Pract 1988;4(Suppl 1):24-8.
28. Goddijn PP, Bilo HJ, Feskens EJ, et al. Longitudinal study on glycaemic control and quality of life in patients with type 2 diabetes mellitus referred for intensified control. Diabet Med 1999;16:23-30.
29. Gradman TJ, Laws A, Thompson LW, et al. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Geriatr Soc 1993;41:1305-12.
30. Petterson T, Lee P, Hollis S, et al. Well-being and treatment satisfaction in older people with diabetes. Diabetes Care 1998;21:930-5.
31. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
32. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
33. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.